Key facts
- This page summarizes John Hamer's Form 4 filing for AbCellera Biologics Inc. (ABCL).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 02 Sep 2021, 18:12.
John Hamer - 31 Aug 2021 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)
- Reporting relationship
- Director
- Issuer ticker
- ABCL
- Reported as of
- 31 Aug 2021
- Net transaction value
- -$5,082,253
- SEC form
- 4
- Accepted by SEC
- 02 Sep 2021, 18:12:34 UTC
- Prior SEC filing
- 22 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tryn Stimart, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
John Hamer filed Form 4 for AbCellera Biologics Inc. (ABCL) on 02 Sep 2021.
Change
- Previous filing in this sequence was filed on 22 Jun 2021.
- Current net transaction value: -$5,082,253.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABCL
transaction
Common Shares
Sale
- Transaction value
- $2,756,901
- Shares
- -162,649
- Change %
- -38%
- Price
- $16.95
- Shares after
- 266,213
- Date
- 31 Aug 2021
- Ownership
- Direct
- Footnotes
- F1, F2
ABCL
transaction
Common Shares
Sale
- Transaction value
- $2,325,352
- Shares
- -137,351
- Change %
- -52%
- Price
- $16.93
- Shares after
- 128,862
- Date
- 01 Sep 2021
- Ownership
- Direct
- Footnotes
- F2, F3
ABCL
holding
Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 14,605,761
- Date
- 31 Aug 2021
- Ownership
- See footnote
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.64 and $17.51. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
Effective August 20, 2021, DCVC Bio GP, LLC ("DCVC Bio GP"), distributed 428,862 common shares of the Issuer to John Hamer in connection with a pro-rata distribution for no consideration to the members of DCVC Bio GP.
Footnote F3
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.56 and $17.38. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP is the general partner of DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP. JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person is one of the managing members of JNK. The managing members of JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that he is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any, by virtue of his interest in DCVC Bio GP and JNK, as applicable.